Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Autor:	Bertucci, François1,2 bertuccif@ipc.unicancer.fr, Fekih, Mahmoud3, Autret, Aurélie1, Petit, Thierry4, Dalenc, Florence5, Levy, Christelle6, Romieu, Gilles7, Bonneterre, Jacques8, Ferrero, Jean-Marc9, Kerbrat, Pierre10, Soulie, Patrick11, Mouret-Reynier, Marie-Ange12, Bachelot, Thomas13, Lerebours, Florence14, Eymard, Jean-Christophe15, Deblock, Mathilde16, Lortholary, Alain17, Hardy-Bessard, Anne-Claire18, Barthelemy, Philippe19, Bonnefoi, Hervé20
Zdroj:	Lancet Oncology. May2016, Vol. 17 Issue 5, p600-611. 12p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu